Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...
Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...
The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...
Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...
Dealbreaker on MSN
Pfizer pockets $1.9B by offloading stake in HIV drugs company majority owned by GSK
Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...
After a years-long revenue drought, there's a light at the end of the tunnel.
If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.
Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results